Masimo announced that Katie Szyman has been appointed the company's next chief executive officer, taking over for interim CEO Michelle Brennan, who has been named chair of Masimo’s board.
Szyman is currently worldwide president of Advanced Patient Monitoring at BD. Previously, she led the Critical Care product group at Edwards Lifesciences, which was acquired by BD in a transaction that closed in September of 2024.
While at Edwards, Szyman accelerated revenue growth in the Critical Care product group through numerous initiatives, including entering adjacent markets through internal and external innovation and introducing the first AI technology cleared by the FDA in the patient monitoring space.
“I have long admired Masimo as an innovation leader, and I could not be more excited about the opportunity to grow the business and deliver improved outcomes for millions more patients around the world. I believe Masimo’s leadership team and bench of talent is top tier, and I am thrilled by the chance to work with and learn from this group," Szyman said.
Masimo said its board remains committed to the previously announced review of alternatives for both the consumer audio and consumer healthcare businesses and has engaged Centerview Partners and Morgan Stanley as financial advisors and Sullivan & Cromwell as a legal advisor.
